⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9680447 | 0.71 | — | — | |
| SCHEMBL10580480 | 0.69 | — | — | |
| SCHEMBL5932570 | 0.69 | — | — | |
| SCHEMBL3495459 | 0.67 | — | — | |
| SCHEMBL7054653 | 0.67 | — | — | |
| SCHEMBL8386929 | 0.67 | — | — | |
| SCHEMBL3408317 | 0.67 | — | — | |
| SCHEMBL956794 | 0.67 | — | — | |
| SCHEMBL92041 | 0.67 | — | — | |
| SCHEMBL8272287 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | claimed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | claimed |
| EP-1718651-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2006-11-08 | — | — | EP | claimed |
| WO-2005077951-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | claimed |
| US-6608033-B1 | Treating coccidiosis in bovine animal by administering effective amount of specified azalide macrolide antibiotic | PFIZER INC. | 2003-08-19 | — | — | US | claimed |
| EP-1078631-A1 | Use of macrolide antibiotics for the treatment or prevention of coccidiosis | Pfizer Products Inc. (US) | 2001-02-28 | — | — | EP | claimed |
| US-5495031-A | Process for the production of 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1996-02-27 | — | — | US | claimed |
| US-5466684-A | 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1995-11-14 | — | — | US | claimed |
| US-5328902-A | Antibiotics | AMERICAN CYANAMID CO. (US) | 1994-07-12 | — | — | US | claimed |
| US-10723704-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180318308-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2018-11-08 | — | — | US | disclosed |
| EP-3365328-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| WO-2017070081-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-0818512-A1 | Quinoline derivative and use of same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996033979-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| EP-0723574-A1 | PROCESS FOR DETECTING MARKED MINERAL OILS AND NEW AZO DYES | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-31 | — | — | EP | disclosed |
| EP-0694589-A1 | Water-soluble disazo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-01-31 | — | — | EP | disclosed |
| US-5487770-A | DETECTING AZO DYE MARKED MINERAL OILS BY TREATING WITH EXTRACTANT CONTAINING WATER, SOLVENT, BASE TO TRANSFER DYE INTO AQUEOUS PHASE | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-30 | — | — | US | disclosed |
| WO-1995010581-A1 | PROCESS FOR DETECTING MARKED MINERAL OILS AND NEW AZO DYES | BASF AKTIENGESELLSCHAFT (DE) | 1995-04-20 | — | — | WO | disclosed |